[EN] ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF<br/>[FR] ISOXAZOLIDINES EN TANT QU'INHIBITEURS DE RIPK1 ET LEUR UTILISATION
申请人:SANOFI SA
公开号:WO2021245070A1
公开(公告)日:2021-12-09
The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn's disease or ulcerative colitis.
[EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2014062511A1
公开(公告)日:2014-04-24
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
Preparation of a Montmorillonite-Modified Chitosan Film-Loaded Palladium Heterogeneous Catalyst and its Application in the Preparation of Biphenyl Compounds
montmorillonite. The results showed that the catalyst has good tensile strength, thermal stability, catalytic activity, and recycling performance and is a green catalytic material with industrial application potential.